Clinical Observation of Montelukast for Children with Henoch-schonlein Purpura

OBJECTIVE:To observe curative efficacy of montelukast for children with henoch-schonlein purpura(HSP).METHODS:70 HSP children were randomized into observation group and control group.All the children got fundamental comprehensive treatment.Observation group was additionally given Montelukast chewable tablets 5 mg per time,once a day,before bedtime,for 4 weeks.The plasma levels of T cell subset,curative efficacy and adverse drug reaction were observed before and after treatment.RESULTS:4 weeks after treatment,the total effective rate of observation group was significantly higher than that of control group(P0.05).The plasma levels of CD4+ and CD4+/CD8+ increased significantly in both groups,but the level of CD8+ was the opposite after treatment(P0.05 or P0.01).The improvement of CD4+,CD8+and CD4+/CD8+ in observation group were much better than in control group(P0.05).No serious ADR was found.There was no significant difference in the incidence of ADR was between 2 groups(P0.05).CONCLUSIONS:Montelukast shows certain curative effect and safety on HSP and can improve the clinic sign and symptom obviously.May its mechanism is related to regulating the levels of T cell subset and enhancing the cellular immune function of the body.